Exiger warns the U.S. is overly reliant on foreign countries to make key components of crucial medications as the Trump ...

The pharmaceutical industry is on the brink of massive transformation driven by cutting-edge technology and strategic ...

Divi's Labs said it will invest Rs 650-700 crore in capacity expansion and that it eyes significant revenue boost ...

Mid-sized Indian pharma firms revamp strategies amid US tariff concerns, focusing on NCDs, API manufacturing, emerging ...

Experts say the tariffs are unlikely to bring back production of generic medicines, given their slim profit margins ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

The Illinois expansion will happen at the company’s headquarter campus in Abbott Park. It's also growing in Dallas.

With extensive experience in manufacturing APIs, advanced intermediates and specialty chemicals, SCI Pharmtech is one of ...

Divi's Laboratories signs a long-term supply agreement with a global pharmaceuticals company for advanced intermediates. The deal is expected to bring significant revenue to Divi's.

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

YJ Biotechnology has been transforming regenerative medicine with its cost-efficient, internationally-certified and ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.